USFDA approves this drug for all heart patients to cut death, hospitalization risk

Jardiance also faces competition from AstraZeneca Plc's drug Farxiga, which has approval for patients with symptomatic heart failure.

220
USFDA Approval
USFDA Approval

Last Updated on October 17, 2024 by The Health Master

The U.S. health regulator said on Thursday it had approved Eli Lilly and partner Boehringer Ingelheim’s drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure.

Originally approved by the U.S. Food and Drug Administration (USFDA) in 2014 for type 2 diabetes patients, the drug’s use was expanded last year to some adults living with heart failure with reduced ejection fraction, which happens when the muscle of the left ventricle is not pumping as well as normal.

“While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure,” said Norman Stockbridge, director of the USFDA’s Division of Cardiology and Nephrology.

The expansion on Thursday now increases its market size to cover a very large patient population of about 6.2 million people, as per Centers for Disease Control and Prevention data.

Jardiance also faces competition from AstraZeneca Plc’s drug Farxiga, which has approval for patients with symptomatic heart failure.

Eli Lilly recorded nearly $1.5 billion in revenue for Jardiance in 2021, while Farxiga garnered twice that amount for AstraZeneca.

USFDA gives nod to Zydus to market Dapagliflozin tablets

USFDA gives nod to Strides Pharma for Amantadine HCL Softgel Capsules

USFDA gives nod to Lupin for sNDA for Solosec

USFDA gives nod to this Molecule to treat retinal vascular diseases

USFDA authorised Bebtelovimab as antibody drug

USFDA gives nod to Zydus for Roflumilast Tablets

DCGI announces classification for 133 Medical Devices in general hospital and orthopaedic instruments

USFDA gives nod to Zydus to market Dapagliflozin tablets

CDSCO gives nod to Cipla to conduct study on Paxlovid

IPA to organise 7th Global Pharmaceutical Quality Summit

BIS sets standard for these Medical Devices

The mandatory QR codes on APIs

NPPA fixes retail price of 19 formulations: February 2022

ICMR to conduct Clinical Trial for new drugs regimen for MDR TB

PCB issues directions to Pharma Companies to comply with norms

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news